LEXICON PHARMACEUTICALS, INC. LXRX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, LEXICON PHARMACEUTICALS, INC. reported revenue across 1 business segments; the largest, Reportable Segment, was $49.8M, 100.0% of the filed sum (+60.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$49.8M100.0%+60.2% yoy
Members sum to the consolidated $49.8M for this period.
- Reportable Segment-$48.9M100.0%-75.2% yoy
Members sum to the consolidated -$48.9M for this period.
- License$45M90.6%+80.0% yoy
- Product$4.65M9.4%-22.6% yoy
Members sum to the consolidated $49.8M for this period.
- Reportable Segment$21.1M100.0%+1572.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.